Dr. Kondziolka on Therapy for Patients With Melanoma Who Have Brain Mets

Doug Kondziolka, MD
Published: Friday, Jun 30, 2017



Doug Kondziolka, MD, professor and vice chair of Clinical Research, NYU Langone Medical Center, discusses therapeutic approaches for patients with melanoma who have brain metastases.

Findings show that patients with BRAF-mutant melanoma who are often on a targeted therapy are still prone to developing brain metastases, Kondziolka explains. These can be treated with focused radiation or tumor removal if the tumor is of a larger size. For patients on immunotherapy, focused radiation can also be effective. What the difference is with these approaches is the effect it has on the tumor, which could possibly be swelling in the brain.

While immunotherapies are effective in patients with melanoma, these treatments might have a more robust impact on the brain.


Doug Kondziolka, MD, professor and vice chair of Clinical Research, NYU Langone Medical Center, discusses therapeutic approaches for patients with melanoma who have brain metastases.

Findings show that patients with BRAF-mutant melanoma who are often on a targeted therapy are still prone to developing brain metastases, Kondziolka explains. These can be treated with focused radiation or tumor removal if the tumor is of a larger size. For patients on immunotherapy, focused radiation can also be effective. What the difference is with these approaches is the effect it has on the tumor, which could possibly be swelling in the brain.

While immunotherapies are effective in patients with melanoma, these treatments might have a more robust impact on the brain.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x